---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-067468"
form_type: "8-K"
ticker: "EYPT"
cik: "0001314102"
company_name: "EyePoint, Inc."
filed_at: "2023-12-04T23:59:59+00:00"
generated_at: "2026-06-07T18:37:11.139188+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# EyePoint reports positive Phase 2 DAVIO 2 topline for EYP-1901 in wet AMD; all endpoints met

## Summary
- Both EYP-1901 doses (2mg and 3mg) achieved non-inferiority in BCVA vs aflibercept (difference of -0.3 and -0.4 letters).
- Over 80% reduction in treatment burden; 65%/64% of eyes supplement-free up to six months for 2mg/3mg.
- No EYP-1901-related ocular or systemic SAEs; favorable safety profile.
- Phase 3 pivotal trial for wet AMD planned for H2 2024; DME trial starts Q1 2024; NPDR data Q2 2024.

## SEC filing metadata
- accession: 0000950170-23-067468
- form_type: 8-K
- ticker: EYPT
- cik: 0001314102
- company_name: EyePoint, Inc.
- filed_at: 2023-12-04T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1314102/000095017023067468/0000950170-23-067468-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1314102/000095017023067468/eypt-20231204.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-067468
- JSON: https://secwatch.observer/filing/0000950170-23-067468.json
- Plain text: https://secwatch.observer/filing/0000950170-23-067468.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.